Bills to Regulate Managed Care Are Introduced

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

WASHINGTON--Managed care seems a topic certain to generate bipartisan attention during the 105th Congress, with several bills already introduced and others on the way.

WASHINGTON--Managed care seems a topic certain to generate bipartisanattention during the 105th Congress, with several bills already introducedand others on the way.

Two separate bills aimed specifically against outpatient mastectomieswere introduced on the opening day of the new Congress. Three New YorkRepublicans, Sen. Alfonse D'Amato, Rep. Susan Molinari, and Rep. SusanKelly, introduced the Women's Health and Cancer Rights Act of 1997 in theHouse and Senate. Rep. Rosa DeLauro (D-Conn) and Rep. Marge Roukema (R-NJ)co-sponsored similar legislation in the House.

Both bills would require health insurers to provide coverage for a minimumof 48 hours following a mastectomy. In addition, the D'Amato-Molinari-Kellybill would bar the discharge of mastec-tomy patients under any circumstances,and after any amount of time, without the consent of both the patient andher physician, so long as the stay "is medically appropriate."

The bill also guarantees coverage for reconstructive surgery for mastectomypatients and requires insurance coverage of second opinions for all cancers.

Rep. Fortney H. "Pete" Stark (D- Calif), the ranking minoritymember on the House Ways and Means health subcommittee, introduced a comprehensivebill called the Managed Care Consumer Protection Act of 1997.

Among the provisions of the bill:

  • Plans would have to provide patients and physicians with a writtendescription of utilization review policies, clinical review criteria, andthe process used to review medical services.
  • A sufficient number, distribution, and variety of qualified healthcare providers must be available, including in rural areas, to ensure thatall enrollees receive all covered services on a timely basis.
  • A notice to a participating provider of termination or nonrenewal ofa contract would have to include reasons for the action.
  • Plans could not use any contractual agreements or written or oral statements"to prohibit, restrict, or interfere with any medical communicationsbetween physicians, patients, plans, or state or federal authorities."
Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content